Relugolix, sold under the brand names Orgovyx and Relumina among others, is a gonadotropin-releasing hormone antagonist (GnRH receptor antagonist) medication which is used in the treatment of prostate cancer in men and uterine fibroids in women.[4][1][6] It is taken by mouth.[1][6]
Side effects of relugolix include menstrual abnormalities, hot flashes, excessive sweating, headache, and decreased bone mineral density.[6][1] Relugolix is a GnRH antagonist, or an antagonist of the gonadotropin-releasing hormone receptor.[1] Unlike most other GnRH modulators, but similarly to elagolix (brand name Orilissa), relugolix is a non-peptide, small-molecule compound and is orally active.[7][8][9] It suppresses sex hormone levels to the postmenopausal or castrate range in both women and men.[1][10][4]
Relugolix was approved for use for the treatment of uterine fibroids in Japan in January 2019, and for the treatment of prostate cancer in the United States in December 2020.[11][12]
^ abcdefghijBarra F, Seca M, Della Corte L, Giampaolino P, Ferrero S (August 2019). "Relugolix for the treatment of uterine fibroids". Drugs of Today. 55 (8): 503–512. doi:10.1358/dot.2019.55.8.3020179. PMID 31461087. S2CID 201654739.
^"Notice: Multiple additions to the Prescription Drug List (PDL) [2023-12-22]". Health Canada. 22 December 2023. Retrieved 3 January 2024.
^"Summary Basis of Decision (SBD) for Orgovyx". Health Canada. 16 February 2024. Retrieved 24 February 2024.
^ abc"Orgovyx- relugolix tablet, film coated". DailyMed. Retrieved 25 May 2021.
^Cite error: The named reference Orgovyx EPAR was invoked but never defined (see the help page).
^ abc"Relumina (relugolix) Information" (PDF). ASKA Pharmaceutical (in Japanese). January 2019. Archived from the original (PDF) on 16 February 2019. Retrieved 16 February 2019.
^Cite error: The named reference pmid21657270 was invoked but never defined (see the help page).
^Cite error: The named reference pmid24333551 was invoked but never defined (see the help page).
^Cite error: The named reference pmid29232843 was invoked but never defined (see the help page).
^Cite error: The named reference pmid26502357 was invoked but never defined (see the help page).
Relugolix, sold under the brand names Orgovyx and Relumina among others, is a gonadotropin-releasing hormone antagonist (GnRH receptor antagonist) medication...
symptoms of metastases. In these people, GnRH antagonists like degarelix or relugolix are given instead, and can also rapidly reduce testosterone levels. Reducing...
introduction of elagolix in the United States and Canada was followed by that of relugolix (brand name Relumina), the next second-generation GnRH antagonist, in...
Global Information
